The VALIANT phase 3 RCT shows that proximal C3 inhibition with pegcetacoplan leads to a significantly greater reduction in proteinuria compared with placebo in patients with C3G and primary immune-com...

2025 was rich in successful stories. Here are the top 10 that impressed our audience.

Holy Mackerel! This week we will discuss fish oil use in maintenance hemodialysis patients. Could this be the one thing that bends the curve on CV mortality, or is it just a red herring?

KDIGO 2025 is here. IgAN management is evolving with precision risk tools, new therapies, and a stronger focus on kidney protection. Check out the visual abstract created by Natalia Nombera

This week, we will discuss an old dilemma in nephrology. To restrict or supplement the proteins? Premise: advanced CKD and dialysis.

We like protein, or do we? Low protein, high protein, supplements…what’s a nephrologist to do?

Help keep NephJC a vital, original, and unbiased source of medical education.

This week, we will discuss the AHA/ACC 2025 hypertension guideline update. Wow, have eight years flown by?

This week, we will discuss the ACHIEVE trial. Will spironolactone achieve CV benefits in ESRD?

JAMA 2023 Dec 19;330(23):2258-2266 doi: 10.1001/jama.2023.23651. Effect of Dietary Sodium on Blood Pressure: A Crossover Trial Deepak K Gupta ,  Cora E Lewis ,  Krista A Varady ,&nbsp...